ConforMIS Inc (NASDAQ:CFMS) – Equities research analysts at Oppenheimer boosted their FY2018 EPS estimates for ConforMIS in a research note issued on Thursday. Oppenheimer analyst S. Lichtman now expects that the medical instruments supplier will post earnings per share of ($0.82) for the year, up from their prior estimate of ($1.01). Oppenheimer currently has a “Buy” rating and a $4.00 price objective on the stock.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03. The firm had revenue of $20.80 million during the quarter, compared to the consensus estimate of $20.07 million. ConforMIS had a negative return on equity of 78.44% and a negative net margin of 68.59%. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.37) earnings per share.

A number of other equities analysts also recently commented on the stock. Canaccord Genuity reduced their target price on shares of ConforMIS from $5.00 to $4.00 and set a “hold” rating for the company in a report on Thursday. BTIG Research reiterated a “hold” rating on shares of ConforMIS in a report on Thursday, November 2nd. Zacks Investment Research downgraded shares of ConforMIS from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. Finally, JPMorgan Chase & Co. downgraded shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. ConforMIS currently has a consensus rating of “Hold” and a consensus target price of $4.88.

Shares of ConforMIS (CFMS) opened at $1.38 on Monday. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52. ConforMIS has a fifty-two week low of $1.15 and a fifty-two week high of $8.61.

A number of institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its stake in shares of ConforMIS by 2.0% during the second quarter. Wells Fargo & Company MN now owns 55,021 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 1,091 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of ConforMIS by 21.4% during the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 6,535 shares during the last quarter. Rhumbline Advisers grew its stake in shares of ConforMIS by 21.8% during the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after acquiring an additional 8,017 shares during the last quarter. State Street Corp grew its stake in shares of ConforMIS by 1.5% during the second quarter. State Street Corp now owns 594,583 shares of the medical instruments supplier’s stock worth $2,550,000 after acquiring an additional 8,693 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of ConforMIS by 31.1% during the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 9,500 shares during the last quarter. Institutional investors and hedge funds own 26.99% of the company’s stock.

In other ConforMIS news, CEO Mark A. Augusti sold 16,548 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total value of $37,563.96. Following the completion of the transaction, the chief executive officer now directly owns 285,007 shares in the company, valued at $646,965.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Cerveny sold 16,392 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $3.17, for a total transaction of $51,962.64. Following the completion of the transaction, the insider now owns 151,408 shares of the company’s stock, valued at $479,963.36. The disclosure for this sale can be found here. Insiders sold 93,291 shares of company stock valued at $248,077 over the last quarter. 9.55% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/02/12/brokers-set-expectations-for-conformis-incs-fy2018-earnings-cfms.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.